RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/15964478http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/15964478http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/15964478http://www.w3.org/2000/01/rdf-schema#comment"The ability of antibodies elicited against the rabies human diploid cell vaccine (HDCV) to neutralise European bat Lyssaviruses (EBLV types-1 and -2), Australian bat Lyssavirus and classical rabies virus (RABV) has been evaluated using modified fluorescent antibody virus neutralisation (mFAVN) assays. Ninety-six percent (48 of 50) of the human post-vaccinated sera tested cross-neutralised these viruses (>or=0.5 IU/ml). Cross-protection experiments using inbred mice (RIII, k/k haplotype) were also assessed. Mice were given HDCV (twice by the intra-peritoneal route) and challenged (intra-cranially or peripherally) with a lethal dose (25 MLD(50)) of the individual viruses. The vaccine conferred statistically significant protection in 80--100% of animals challenged via the peripheral route. Levels of protection were lower following intra-cranial (i.c.) challenge. Our data provides strong evidence for broad spectrum cross-neutralisation and cross-protection of phylogroup I lyssaviruses using rabies HDCV."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.org/dc/terms/identifier"doi:10.1016/j.vaccine.2005.03.037"xsd:string
http://purl.uniprot.org/citations/15964478http://purl.org/dc/terms/identifier"doi:10.1016/j.vaccine.2005.03.037"xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/author"Brookes S.M."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/author"Brookes S.M."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/author"Fooks A.R."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/author"Fooks A.R."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/author"Johnson N."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/author"Johnson N."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/author"McElhinney L.M."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/author"McElhinney L.M."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/author"Parsons G."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/author"Parsons G."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/date"2005"xsd:gYear
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/date"2005"xsd:gYear
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/name"Vaccine"xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/name"Vaccine"xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/pages"4101-4109"xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/pages"4101-4109"xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/title"Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/title"Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses."xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/volume"23"xsd:string
http://purl.uniprot.org/citations/15964478http://purl.uniprot.org/core/volume"23"xsd:string